National Bank Financial Reiterates Outperform Rating for Theratechnologies (TH)

Share on StockTwits

Theratechnologies (TSE:TH)‘s stock had its “outperform” rating restated by research analysts at National Bank Financial in a note issued to investors on Wednesday, June 20th. They currently have a C$14.25 target price on the stock. National Bank Financial’s price objective suggests a potential upside of 12.38% from the company’s previous close. National Bank Financial also issued estimates for Theratechnologies’ FY2018 earnings at $0.08 EPS and FY2019 earnings at $0.48 EPS.

Several other equities research analysts also recently commented on the stock. Canaccord Genuity upped their price target on shares of Theratechnologies from C$9.50 to C$13.00 in a research report on Wednesday, March 7th. CIBC upped their price objective on shares of Theratechnologies from C$10.30 to C$15.00 in a research note on Wednesday, March 7th.

TSE TH opened at C$12.68 on Wednesday. Theratechnologies has a 52 week low of C$4.96 and a 52 week high of C$14.75.

Theratechnologies (TSE:TH) last released its earnings results on Thursday, April 5th. The company reported C($0.04) EPS for the quarter, beating the consensus estimate of C($0.05) by C$0.01. The business had revenue of C$10.22 million during the quarter, compared to analyst estimates of C$11.20 million. Theratechnologies had a negative net margin of 33.47% and a negative return on equity of 38.09%.

In other news, Director Jean-Denis Talon acquired 2,700 shares of the firm’s stock in a transaction that occurred on Monday, April 9th. The stock was acquired at an average cost of C$9.44 per share, with a total value of C$25,488.00. Over the last ninety days, insiders have purchased 4,100 shares of company stock valued at $37,792.

About Theratechnologies

Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. The company's lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada.

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with's FREE daily email newsletter.

Leave a Reply